Cas:1162-65-8 AFLATOXIN B1 manufacturer & supplier

Chemical Name:AFLATOXIN B1

CAS.NO:1162-65-8

Synonyms:Cyclopenta[c]furo[3′,2′:4,5]furo[2,3-h][1]benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR,9aS)-;Aflatoxin B1;Aflatoxin B1 Crystalline;(-)-Aflatoxin B1;(6aR,9aS)-4-Methoxy-2,3,6a,9a-tetrahydrocyclopenta[c]furo[3′,2′:4,5]furo[2,3-h]chromene-1,11-dione;Aflatoxin B1, crystalline;MFCD00869647;Aflatoxin;EINECS 214-603-3

Molecular Formula:C₁₇H₁₂O₆

Molecular Weight:312.274

HS Code:

Physical and Chemical Properties:

Melting point:268-269 ℃

Boiling point:528.2±50.0 °C at 760 mmHg

Density:1.6±0.1 g/cm3

Index of Refraction:1.687

PSA:74.97000

Exact Mass:312.063385

LogP:0.45

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3462 6.1/PG 1

Packing Group:I

Contact us for information like Cyclopenta[c]furo[3′,2′:4,5]furo[2,3-h][1]benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR,9aS)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 214-603-3 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Aflatoxin B1 Crystalline Use and application,Aflatoxin B1, crystalline technical grade,usp/ep/jp grade.

Related News: “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” AFLATOXIN B1 manufacturer “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” AFLATOXIN B1 supplier Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage. AFLATOXIN B1 vendor High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies. AFLATOXIN B1 factory To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early.